Literature DB >> 12463296

First-line pharmacotherapy for tobacco use and dependence.

Steve A Watts1, Sara L Noble, Patrick O Smith, Marilyn Disco.   

Abstract

First-line pharmacotherapies for tobacco use and dependence (namely, nicotine patch, nicotine gum, nicotine inhaler, nicotine nasal spray, and sustained-release bupropion) are safe and have been empirically determined to be efficacious and should always be considered part of a tobacco treatment intervention program unless contraindicated. Studies published subsequent to the literature synthesized in TTUD support previously determined efficacy of first-line pharmacologic medications for treatment of tobacco use and dependence. Further studies will be necessary to define clearly the efficacy and relative safety of combination treatments.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12463296

Source DB:  PubMed          Journal:  J Am Board Fam Pract        ISSN: 0893-8652


  5 in total

Review 1.  Tobacco Use Cessation and Prevention - A Review.

Authors:  Sabiha Shaheen Shaik; Dolar Doshi; Srikanth Reddy Bandari; Padma Reddy Madupu; Suhas Kulkarni
Journal:  J Clin Diagn Res       Date:  2016-05-01

Review 2.  Combination treatment for nicotine dependence: state of the science.

Authors:  Karen S Ingersoll; Jessye Cohen
Journal:  Subst Use Misuse       Date:  2005       Impact factor: 2.164

Review 3.  A review of smoking cessation interventions.

Authors:  Ashish Maseeh; Gagandeep Kwatra
Journal:  MedGenMed       Date:  2005-06-07

Review 4.  Multidisciplinary care of the patient with chronic obstructive pulmonary disease.

Authors:  Anne Marie Kuzma; Yvonne Meli; Catherine Meldrum; Patricia Jellen; Marianne Butler-Lebair; Debra Koczen-Doyle; Peter Rising; Kim Stavrolakes; Frances Brogan
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

Review 5.  Treating tobacco dependence: guidance for primary care on life-saving interventions. Position statement of the IPCRG.

Authors:  O C P Van Schayck; S Williams; V Barchilon; N Baxter; M Jawad; P A Katsaounou; B J Kirenga; C Panaitescu; I G Tsiligianni; N Zwar; A Ostrem
Journal:  NPJ Prim Care Respir Med       Date:  2017-06-09       Impact factor: 2.871

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.